

# ChemModeling

## Compound Collection Analysis and Augmentation

Jon Swanson  
[jon@chemmodeling.com](mailto:jon@chemmodeling.com)  
(636) 329-0300  
ChemModeling, LLC  
April 27, 2009

## Why Analyze and Augment a Collection?

---

- Compound collections are dynamic
  - Compounds deteriorate over time
  - New targets suggest new types of compounds to screen
- Understand overall quality of collection and improve it
  - Higher quality hits and follow-up SAR development
  - Increased hit-rate from high quality lead-like matter
  - Confidence in identity of compounds (not break-down products)
- Faster in-silico screening
  - Remove compounds medicinal chemists will reject anyway
  - Reduce duplication of pharmacologically similar compounds
  - Clustering and enrichment by target area
- Computational assessment to improve downstream success of lead and pre-clinical candidates


---

ChemModeling

2

Copyright 2009 ChemModeling All Rights Reserved, CONFIDENTIAL

## Library Enhancement Strategy




Compounds can be further subdivided by target

ChemModeling

3

Copyright 2009 ChemModeling All Rights Reserved, CONFIDENTIAL

## Normalization of a Compound Collection



An example entry error from the PhysProp database corrected with fragment based rules

Examples of the effect of tautomeric form on ClogP corrected with ProtoPlex (ProtoPlex derived tautomers are on the left)

ChemModeling

4

Copyright 2009 ChemModeling All Rights Reserved, CONFIDENTIAL

## Toward a Lead-like or Targeted Subset

Compounds in a screening set should have drug-like or lead-like properties

### Lipinski's "Rule of 5" is the best known filtering criteria

Poor absorption or permeation of an orally administered drug is more likely to occur if any two of these criteria are violated:

- Molecular weight is greater than 500
- Lipophilicity is high (ClogP is greater than 5)
- Number of Hydrogen bond donors is greater than 5
- Number of Hydrogen bond acceptors is greater than 10

There are MANY others

=> Rules need to be tailored to specific customers needs

Properties of Oral Drugs Categorized by Gene Family

	90% MW	90% ClogP	90% HBD	90% HBA	90% Rbonds
Aminergic GPCRs	460	5.6	2	6	8
Ion Channels	430	4.7	3	6	7
Nuclear Hormone Receptors	495	7.3	2	6	10
Peptide GPCRs	752	6.5	8	10	17
Phospho-diesterases	465	5.2	2	8	9
Protein Kinases	505	5.7	4	7	9
Serine Proteases	572	4.8	4	8	12

Hopkins, et al, Nature Biotechnology 2006, 7, 805-815

ChemModeling


5

Copyright 2009 ChemModeling All Rights Reserved, CONFIDENTIAL

## Other Factors are also Important

- Fragment Based Filters
  - Unwanted
  - Unstable
  - Toxic groups
- Similarity/Dissimilarity to Known Targets
- Custom Scoring Functions

### ESOL – Estimated Aqueous Solubility



Plot of ESOL predicted solubility implemented in `slnProperty` versus the experimental `logS` values for compounds used as a training set for ALOGPS program from the ALOGPS website.

$$\log(S) = 0.16 - 0.63 * \text{ClogP} \\ - 0.0062 * \text{MW} + 0.066 * \text{RotBonds} \\ - 0.74 \text{ AromaticFraction}$$

AromaticFraction is fraction of heavy atoms in aromatic 6-membered rings

Delaney, J. S. *J. Chem. Inf. Comput. Sci.* 2004, 44, 1000 – 1005.


ChemModeling

6


Copyright 2009 ChemModeling All Rights Reserved, CONFIDENTIAL

## Toward a Representative Subset

Distance-based gridding of chemistry space allows representative selections



A typical cluster-based selection choosing 3 compounds per cluster



Selection based on equally-spaced grid points better samples clusters

Many different types of distances can be employed- 2D Tanimoto fingerprint similarities, topomer distances, SurFlex-Sim similarities, or others.


ChemModeling

7

Copyright 2009 ChemModeling All Rights Reserved, CONFIDENTIAL

## Grid-based Approach Allows Flexibility

Select first from lead-like compounds and fill-in with drug-like compounds in chemistry space not covered by the lead-like selections.



Alternate approaches can be used, such as selecting based on similarity to existing targets and then filling in with lead-like matter.

ChemModeling

8

Copyright 2009 ChemModeling All Rights Reserved, CONFIDENTIAL

## Augmenting a Compound Collection


- Process vendor collection in same manner as corporate collection
- Produce a lead-like subset
- Compare corporate collection to vendor collection
  - Eliminate any vendor compounds that are within specified cut-off distance of corporate collection
- Cluster remaining lead-like, novel subset
  - Grid spacing for vendor collection often looser than for corporate collection
  - Can also fill-in clusters with low occupancy of corporate compounds
- Select compounds from clusters based on client preferences
  - Preferred vendors
  - Best properties
  - Best price
  - Purity

9

Copyright 2009 ChemModeling All Rights Reserved, CONFIDENTIAL

ChemModeling

## Augmentation Can Be Tailored



Include areas not covered by original collection

- Select sequentially
  - Preferred Vendors
  - Preferred Targets
- Select based on target
  - Similarity to known actives
  - Privileged substructures
  - Meet pharmacophore model
  - Meet SAR model
- Select based on properties
  - Preferred vendors
  - Best properties
  - Best price
  - Purity

10

Copyright 2009 ChemModeling All Rights Reserved, CONFIDENTIAL

ChemModeling